Mirimus

Mirimus, Inc. was founded in 2010 with the goal of creating a scalable and cost-effective pipeline for model generation by developing animal models critical for the preclinical evaluation of new therapies, leveraging the power of RNAi and CRISPR technologies. Through cutting-edge technology, robust predictive tools, and vital partnerships, Mirimus is paving the way for the development of safer and more effective therapies by precisely targeting potential toxicity, validation, and disease models.